Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
WEBINAR | Join top cancer researchers to explore advances transforming early discovery, from new targets and models to the therapies of tomorrow
news

Sound Pharmaceuticals receives $1.6 Million Award to treat CF-related tinnitus

Sound Pharmaceuticals has been awarded up to $1.6M from Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation.

hearing loss

The CFFT development award will support the initial testing of SPI-1005 in people with CF who are receiving tobramycin for the treatment of acute pulmonary exacerbations or lung infections. A leading side effect of tobramycin involves damage to the inner ear and is called ototoxicity.

Phase I trial

The Phase 1b STOP Ototoxicity clinical trial will examine the incidence and severity of hearing loss, tinnitus, dizziness or vertigo due to IV tobramycin treatment. SPI-1005 is a novel oral drug that is being developed to reduce the incidence and severity of sensorineural hearing loss and tinnitus in several disease states including ototoxicity, noise and Meniere’s disease.

The STOP Ototoxicity study will be led by Patrick Flume, MD, Professor of Medicine and Pediatrics at MUSC in Charleston, and will enrol a total of 100 subjects at multiple US sites.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

Expert team

Dr Flume is an international expert in CF and pulmonary disease and has co-chaired the development of the CF Foundation’s care guidelines on the treatment of pulmonary exacerbations.

“We are thrilled to have the support of the CF Foundation and Dr Flume on this ground breaking study of tobramycin-induced ototoxicity,” said Jonathan Kil, MD, Sound Pharmaceuticals‘ Co-Founder, CEO and Chief Medical Officer.

CF patients are extremely vulnerable to ototoxicity because they receive repeated courses of aminoglycosides, such as tobramycin or amikacin, through inhaled and injected routes of administration, starting at a very young age.

“This is the first comprehensive US study of ototoxicity in the CF population and we are pleased to be leading it,” said Dr Flume.

 

Ototoxicity

Ototoxicity is common side effect in medical treatments involving chemotherapy, antibiotics and loop diuretics. The combination of these classes of drugs can be contraindicated, especially in conditions where kidney function is impaired. These highly ototoxic medications can result in permanent, and often progressive, inner ear disease. In some cases, the ototoxicity becomes dose-limiting and results in moderate hearing loss that requires a hearing aid, or severe to profound hearing loss that requires a cochlear implant.

Currently, there are no FDA approved drugs for the prevention or treatment of any type of sensorineural hearing loss or tinnitus including ototoxicity or Meniere’s disease.